Caption
: Recruiting trial
= 
; Ongoing trial
= 
-
- Fludarabine, Mitoxantrone and Cyclophosphamide (FMC) for T-CLL (T-cell chronic lymphocytic leukaemia) and T-PLL (T-cell prolymphocytic leukemia) followed by Campath 1 St
- Hanusch Krankenhaus
- Ludwig Boltzmann Institut für Leukämieforschung und Hämatologie
- More details
-
- BELGIUM
- ARRONDISSEMENT BRUSSELS-CAPITAL
- BRUSSELS
- GRASPALL Study : administration of L-Asparaginase entrapped into red blood cell for the treatment of recurrent Acute Lymphoblastic Leukemia (Phase II)
- Hôpital Universitaire des Enfants Reine Fabiola - HUDERF
- Service d'Hématologie et d'Immunologie pédiatrique
- More details
-
- DENMARK
- Hovedstaden
- COPENHAGEN
- ALL2008 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion (Phase III) - DK -
- Rigshospitalet
- Paediatrisk klinik I
- More details
-
- DENMARK
- Hovedstaden
- COPENHAGEN
- Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol - DK -
- Rigshospitalet
- Paediatrisk klinik I
- More details
-
- ALL2008 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion (Phase III) - FI -
- HUS - Hospital for Children and Adolescents
- Hospital for Children and Adolescents
- More details
-
- Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol - FI -
- HUS - Hospital for Children and Adolescents
- Hospital for Children and Adolescents
- More details
-
- An open-label, randomized phase II/III-study to compare the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL)
- CHU de Rennes - Hôpital Sud
- Hématologie pédiatrique - Oncologie pédiatrique
- More details
-
- FRANCE
- FRANCHE-COMTE
- BESANÇON
- Treatment of non-hodgkinian malignant lymphomas of low malignity grade: GOELNH LOGLOC (Phase III) - Terminated -
- CHRU Besançon - Hôpital Jean Minjoz
- Service d'hématologie
- More details
-
- FRANCE
- ILE-DE-FRANCE
- LE CHESNAY
- EWALL-PH-01: An open label phase II study to evaluate the efficacy and safety of induction and consolidation therapy with Dasatinib in combination with chemotherapy in patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCRABL+) Acute Lymphoblastic Leukemia (ALL) - FR
- Centre hospitalier de Versailles - Hôpital André Mignot
- Service d'hématologie et oncologie
- More details
-
- FRANCE
- ILE-DE-FRANCE
- PARIS
- Treatment of aggressive lymphoma in adults: NHL 98
- CHU Paris-GH St-Louis Lariboisière F.Widal - Hôpital Saint-Louis
- Institut Universitaire d'Hématologie
- More details
-
- FRANCE
- ILE-DE-FRANCE
- VILLEJUIF
- A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma
- CRLCC Institut de cancérologie Gustave Roussy
- Service d'hématologie
- More details
-
- FRANCE
- ILE-DE-FRANCE
- VILLEJUIF
- Phase I/II dose-escalation study of oral administration of the Pan-Histone Deacetylase (HDAC) Inhibitor S 78454 in Hodgkin's Disease, non-Hodgkin Lymphoma and Chronic Lymphocytic Leukaemia
- CRLCC Institut de cancérologie Gustave Roussy
- Service d'hématologie
- More details
-
- FRANCE
- ILE-DE-FRANCE
- VILLEJUIF
- Open Label, Pilot Phase II Study of Glivec in Children and Adolescents with Life ThreateningDiseases Known to be associated with one or more Glivec-Sensitive Tyrosine Kinases
- CRLCC Institut de cancérologie Gustave Roussy
- Département de cancérologie de l'enfant et de l'adolescent
- More details
-
- FRANCE
- ILE-DE-FRANCE
- VILLEJUIF
- (APL-A-005-02) Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukaemia -Terminated -
- CRLCC Institut de cancérologie Gustave Roussy
- Département de cancérologie de l'enfant et de l'adolescent
- More details
-
- FRANCE
- PAYS DE LA LOIRE
- NANTES
- Etude médicament de Phase II multicentrique, en ouvert, prospective non randomisée testant l'intérêt d'une combinaison de Chimio-immunothérapie comportant l'anticorps anti-CD22 Epratuzumab pour le traitement de patients adultes pésentant une leucémie aigue lymphoblastique de type B CD22+ en rechute ou réfractaire : Etude CHEPRALL, une étude GRAALL - FR
- CHU de Nantes
- CHU Nantes
- More details
-
- FRANCE
- PAYS DE LA LOIRE
- NANTES
- PRELUDE : A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
- CHU de Nantes - Hôtel Dieu
- Service d'hématologie clinique
- More details
-
- FRANCE
- PAYS DE LA LOIRE
- NANTES
- Cloric : A Phase II Open-Label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-Risk AML, MDS or ALL
- CHU de Nantes - Hôtel Dieu
- Service d'hématologie clinique
- More details
-
- FRANCE
- PAYS DE LA LOIRE
- NANTES
- Phase I / II dose-escalation study evaluating the efficacy and safety of a radio-immunotherapy treatment with 90Y-Epratuzumab for adult patients with relapsed or refractory CD22+ B acute lymphoblastic leukemia.
- CHU de Nantes - Hôtel Dieu
- Service d'hématologie clinique
- More details
-
- FRANCE
- POITOU-CHARENTES
- POITIERS
- Dasatinib (BMS-354825) combined with SMO inhibitor (BMS-833923; XL139) in CML with resistance or suboptimal response to a prior TKI (phase I/II) - FR
- CHU de Poitiers
- Service d'oncologie hématologique et de thérapie cellulaire
- More details
-
- FRANCE
- PROVENCE-ALPES-COTE D'AZUR
- MARSEILLE
- Phase II pharmacokinetic study to assess doxorubicin clearance age-dependency in pediatric patients with solid tumours and leukemia - FR
- CHU de Marseille - Hôpital de la Timone
- Service d'oncologie pédiatrique
- More details
-
- FRANCE
- PROVENCE-ALPES-COTE D'AZUR
- MARSEILLE
- Intensive sequential chemotheray in non hodgkin lymphoma (NLH) of patients suffering from HIV- CIS VIH 02 (Phase IV) - trial stopped -
- CRLCC Institut Paoli Calmettes
- Unité d'onco-hématologie II
- More details
-
- GRASPALL Study : administration of L-Asparaginase entrapped into red blood cell for the treatment of recurrent Acute Lymphoblastic Leukemia (Phase II)
- CHU de Lyon-GH Est - Institut d'Hématologie et d'Oncologie pédiatrique
- Service d'immuno-hématologie pédiatrique et de transplantation de moelle osseuse
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- An open-label, randomised crossover pharmacokinetic, palatability and safety study to assess the bioavailability of a new 6MP oral liquid formulation by comparison to a currently registered 6MP 50 mg adult tablet (part A) followed by an open, non-randomised multiple-doses study with adjusted doses of 6MP oral liquid formulation (part B) in children with acute lymphoblastic leukaemia - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory acute leukemia - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- AmbiGUARD - Étude multicentrique de phase III randomisée en double aveugle contrôlée contre placebo, évaluant l'efficacité la sécurité et la tolérance de l'amphotéricine B liposomale (AmBisome®) à titre prophylactique pour la prévention des infections fongiques invasives chez les patients recevant une chimiothérapie d'induction (en vue d'une rémission) pour une leucémie aiguë lymphoblastique.
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- An open-label, randomized, phase III study of Inotuzumab Ozogamicin administred in combination with Rituximab compared to defined investigator choice therapy in subjects with relapsed or refractory CD22-positive aggressive Non-Hodgkin Lymphoma who are not candidates for intensive high dose chemotherapy - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Phase I Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel HSP90-Inhibitor, Administered Orally, in Patients with Advanced Solid Tumours or Lymphoma - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A Phase I dose-escalation study of IPH2102, a fully human anti-KIR monoclonal antibody (CHO manufacturing), in patients with various hematologic or solid malignancies - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Bortezomib (Velcade®): a feasibility and phase II study in childhood relapsed acute lymphoblastic leukemia - FR
- Not yet identified - FR
- More details
-
- FRANCE
- RHONE-ALPES
- PIERRE-BENITE
- A phase Ia/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ALL, and other hematologic malignancies - FR
- CHU de Lyon Sud
- Hématologie Clinique, Pavillon Marcel Bérard 1G
- More details
-
- FRANCE
- RHONE-ALPES
- SAINT PRIEST EN JAREZ
- RV-405 LAL : A phase II, multi-center, open-label, repeat-dose study of Lenalidomide (Revlimid ®) plus low-dose Dexamethasone in patients with refractory B-cell lineage acute lymphoblastic leukemia or in relapse after two lines of treatment.
- Institut de Cancérologie de la Loire
- Hématologie
- More details
-
- GERMANY
- Baden-Württemberg
- TÜBINGEN
- Phase I/II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts in patients with treatment refractory hematologic malignancies
- Universitätsklinikum Tübingen
- Medizinische Klinik Abteilung II - Hämatologie, Onkologie und Pulmologie
- More details
-
- GERMANY
- Baden-Württemberg
- TÜBINGEN
- Pegfilgrastim vs. filgrastim - comparison of mobilized blood stem cells in patients with Non-Hodgkin lymphoma (Phase II)
- Universitätsklinikum Tübingen
- Medizinische Klinik Abteilung II - Hämatologie, Onkologie und Pulmologie
- More details
-
- GERMANY
- Baden-Württemberg
- TÜBINGEN
- CD3/CD19 Haplo (E410/2007): Multicenter phase II study of Haploidentical Hematopoietic Cell Transplantation with CD3/CD19 depleted Grafts after a reduced intensity conditioning regimen for adult Patients with Acute Leukemia
- Universitätsklinikum Tübingen
- Medizinische Klinik Abteilung II - Hämatologie, Onkologie und Pulmologie
- More details
-
- MT103-202: An open-label, multicenter phase II study to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BITE) MT1030 (Blinatumomab) in patients with minimal residual disease (MRD) of positive Precursor B-cell Acute Lymphoblastic Leukemia
- Universitätsklinikum Würzburg
- Medizinischen Klinik und Poliklinik II - Hämatologie und Onkologie
- More details
-
- MT103-203 (BLAST): A confirmatory multicenter, single-arm phase II study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of Precursor B-cell Acute Lymphoblastic Leukemia - DE
- Universitätsklinikum Würzburg
- Medizinischen Klinik und Poliklinik II - Hämatologie und Onkologie
- More details
-
- MT103-206: An open label, multicenter, exploratory phase II study to evaluate the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with relapsed/refractory Precursor B-cell Acute Lymphoblastic Leukemia - DE
- Universitätsklinikum Würzburg
- Medizinischen Klinik und Poliklinik II - Hämatologie und Onkologie
- More details
-
- MT103-211: An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE Antibody Blinatumomab in adult patients with relapsed/refractory Precursor B-cell Acute Lymphoblastic Leukemia - DE
- Universitätsklinikum Würzburg
- Medizinischen Klinik und Poliklinik II - Hämatologie und Onkologie
- More details
-
- ALL-REZ BFM 2002: Multicentre Study for Children With Relapsed Acute Lymphoblastic Leukemia
- Charité - Universitätsmedizin Berlin (CVK)
- Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
- More details
-
- A phase I/II pharmacokinetic study of intravenous and oral Forodesine in children with relapsed or refractory Precursor T-cell or B-cell Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma.
- Charité - Universitätsmedizin Berlin (CVK)
- Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
- More details
-
- MT103-205: A single-arm multicentre phase II study preceded by dose evaluation to investigate the efficacy, safety, and tolerability of the BiTE® Antibody Blinatumomab (MT103) in paediatric and adolescent patients with relapsed/refractory Precursor B-cell Acute Lymphoblastic Leukemia - DE
- Charité - Universitätsmedizin Berlin (CVK)
- Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
- More details
-
- GERMANY
- Berlin
- NOT YET IDENTIFIED - DE
- A Multicentre, single arm, observational phase IV study to assess the safety and efficacy of Nelarabine in children and young adults (up to 21 Years of Age) with relapsed or refractory T-Acute Lymphoblastic Leukaemia (T-ALL) or T-Lymphoblastic Lymphoma (T-LBL) - DE
- Not yet identified - DE
- More details
-
- DSHNHL 2002-1 ((Mega-CHOEP Phase III): Randomized phase III study CHOEP-14 + Rituximab vs high-dose chemotherapy followed by autologous stem cell transplantation (Mega-CHOEP-21) + Rituximab in patients with aggressive NHL
- Asklepios Klinik St. Georg
- Abteilung für Hämatologie und Stammzelltransplantation
- More details
-
- TreoALL (GMALL Allo-SCT-Treo-VP16-Cyclo): Allogeneic stem cell transplantation with Treosulfan, VP-16 and Cyclophosphamide for patients with Acute Lymphoblastic Leukemia (ALL) not eligible for TBI-containing conditioning regimen: A Phase II-Study
- Universitätsklinikum Hamburg-Eppendorf
- Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation
- More details
-
- COALL-07-03 : Multicenter Phase III Study for the treatment of children with Acute Lymphoblastic Leukemia
- Universitätsklinikum Hamburg-Eppendorf
- Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie
- More details
-
- COALL 08-09: A randomized multicenter treatment phase II/III study to improve the survival of children with Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology
- Universitätsklinikum Hamburg-Eppendorf
- Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- CAMN107A2101: A phase Ia/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ALL, and other hematologic malignancies - DE
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL SCT Elderly: A Open phase II study to investitage feasibility, safety and efficacy of dose-reduced stem-cell-transplantation (SCT) in elderly patients (biological age > 55 Jahren) with high-, or highly-risk acute lymphoblastic leukemia
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL Marqibo: A phase 2 study to evaluate the safety and efficacy of weekly doses of Marqibo® (vincristine sulfate liposomes injection) in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in second relapse or adult patients with Philadelphia chromosome-negative all who failed two treatment lines of anti-leukemia chemotherapy - Terminated
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- EWALL-PH-01 (GRAALLPHAG06): An open label phase II study to evaluate the efficacy and safety of induction and consolidation therapy with Dasatinib in combination with chemotherapy in patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) - DE
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- MC-PEGASP.1/adults: A Randomised, multicentre, parallel-group, open label, Oncaspar controlled dose ranging trial of three doses of Pegylated recombinant Asparaginase in adult patients with newly diagnosed Acute Lymphoblastic Leukaemia (ALL) (Phase I/II)
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- EWALL-PH-02: An open label phase II study to evaluate the efficacy and safety of induction and consolidation therapy with Nilotinib in combination with Chemotherapy in patients aged 55 years and with Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL-PH-01: Open label phase II study to evaluate the safety of standard induction and consolidation therapy in combination with dasatinib in newly diagnosed adult patients with philadelphia chromosome positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL)
- Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
- Medizinische Klinik II - Hämatologie und Onkologie
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL T-LBL 1/2004: Multicentre trial for treatment optimization in T-Lymphoblastic Lymphoma in adults and adolescents older than 18 years (Phase IV)
- ONKOLOGIKUM
- ONKOLOGIKUM Frankfurt am Museumsufer
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL 07/2003: German multicenter study for treatment optimisation in Acute Lymphoblastic Leukemia in adults and adolescents above 18 years - Treatment optimisation by evaluation of minimal residual disease (Phase IV)
- ONKOLOGIKUM
- ONKOLOGIKUM Frankfurt am Museumsufer
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL B-ALL/NHL 2002: Multicenter study to optimise therapy of B-ALL, Burkitt's NHL and high-grade Non-Hodgkin's Lymphoma in adults (Phase IV)
- ONKOLOGIKUM
- ONKOLOGIKUM Frankfurt am Museumsufer
- More details
-
- GERMANY
- Hessen
- FRANKFURT AM MAIN
- GMALL Elderly 1/2003: Multicenter study to optimize treatment in elderly patients (> 55 years, no upper age limit) with Acute Lymphoblastic Leukemia (Phase IV)
- ONKOLOGIKUM
- ONKOLOGIKUM Frankfurt am Museumsufer
- More details
-
- Prednisolone or Dexamethasone combined with chemotherapy in treating young patients with newly diagnosed Lymphoblastic Lymphoma (Phase III) - Terminated
- Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen
- Abteilung für Pädiatrische Hämatologie und Onkologie
- More details
-
- B-NHL BFM Rituximab: Multicenter phase II therapy study for children with mature B-NHL or B-ALL with a Rituximab - Window before Chemotherapy
- Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen
- Abteilung für Pädiatrische Hämatologie und Onkologie
- More details
-
- GERMANY
- Niedersachsen
- HANNOVER
- CA180-226: A Phase II Study of Dasatinib in children and adolescents with newly diagnosed chronic phase Chronic Myeloid Leukemia (CML) or with Ph+ leukemias resistant or intolerant to Imatinib - DE
- Medizinische Hochschule Hannover
- Klinik für Pädiatrische Hämatologie und Onkologie
- More details
-
- GERMANY
- Nordrhein-Westfalen
- ESSEN
- PETAL - study: Positron emission tomography guided therapy of aggressive Non-Hodgkin's Lymphomas (Phase III)
- Universitätsklinikum Essen
- Klinik für Hämatologie
- More details
-
- GERMANY
- Nordrhein-Westfalen
- KÖLN
- AmBiGuard: A Phase 3, double-blind, multicentre, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of Liposomal Amphotericin B (AmBisome®) for the prevention of Invasive Fungal Infections (IFIs) in subjects receiving remission-induction chemotherapy for Acute Lymphoblastic Leukemia - DE
- Universitätsklinikum Köln
- Klinik I für Innere Medizin
- More details
-
- GERMANY
- Nordrhein-Westfalen
- MÜNSTER
- EPOC-MS-001: Phase II pharmacokinetic study to assess the age-dependency in the clearance of Doxorubicin in paediatric patients with Solid Tumours and Leukaemia - DE
- Universitätsklinikum Münster
- AG Prof. Boos: Experimentelle pädiatrische Onkologie
- More details
-
- DSHNHL 1999-1A (RICOVER-60): Therapy Optimization Study of 6 x CHOP in 14 days interval with or without Rituximab in patients aged 61-80 years with aggressive Non-Hodgkin-Lymphoma - Terminated
- Universitätsklinikum des Saarlandes
- Klinik für Innere Medizin I
- More details
-
- A phase I/II multicentre study of autologous stem cell transplantation followed by nonmyeloablative allogeneic stem cell transplantation for patients with relapsed or refractory Lymphoma
- Universitätsklinikum Leipzig AöR
- Abteilung Hämatologie, Internistische Onkologie und Hämostaseologie
- More details
-
- GERMANY
- Schleswig-Holstein
- KIEL
- ALL-BFM-2000: Phase III study for the treatment of children and adolescents with Acute Lymphoblastic Leukemia (ALL)
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Klinik für Allgemeine Pädiatrie
- More details
-
- GERMANY
- Schleswig-Holstein
- KIEL
- INTERFANT-06: International treatment protocol for infants under one year with Acute Lymphoblastic or Biphenotypic Leukemia
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Klinik für Allgemeine Pädiatrie
- More details
-
- GERMANY
- Schleswig-Holstein
- KIEL
- EsPhALL: An open-label, randomised phase II/III study to compare the safety and efficacy of Imatinib with chemotherapy in pediatric patients with Ph+ / BRC-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Klinik für Allgemeine Pädiatrie
- More details
-
- GERMANY
- Schleswig-Holstein
- KIEL
- AIEOP-BFM ALL 2009 : International collaborative treatment protocol for children and adolescents with Acute Lymphoblastic Leukemia (Phase III)
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Klinik für Allgemeine Pädiatrie
- More details
-
- GERMANY
- Schleswig-Holstein
- KIEL
- ALL-SZT BFM 2003: Allogenic stem cell transplantation in children and adolescents with Acute Lymphoblastic Leukemia (Phase III)
- Universitätsklinikum Schleswig-Holstein - Campus Kiel
- Klinik für Allgemeine Pädiatrie
- More details
-
- PACE: A pivotal phase 2 trial of ponatinib (AP24534) in patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia - DE
- Universitätsklinikum Jena
- Abteilung Hämatologie und Internistische Onkologie
- More details
-
- IRELAND
- County Dublin
- DUBLIN
- Comparison of different combination chemotherapy regimens in treating infants with acute lymphoblastic leukemia
- Our Lady's Children's Hospital
- National Oncology/ Bone Marrow Transplant Centre and Haematology Department
- More details
-
- ITALY
- EMILIA ROMAGNA
- BOLOGNA
- Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Azienda Ospedaliera di Bologna - Policlinico S. Orsola-Malpighi
- Dipartimento di Ematologia e Scienze Oncologiche
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory acute leukemia - IT
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia - IT
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Dasatinib (BMS-354825) combined with SMO inhibitor (BMS-833923; XL139) in CML with resistance or suboptimal response to a prior TKI (phase I/II) - IT
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A phase I/II, open-label, dose-escalating study to evaluate the safety, tolerability and pharmacokinetics of oral midostaurin and to evaluate the preliminary clinical and pharmacodynamic response in pediatric patients with relapsed or refractory acute leukemia - IT
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL - IT
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL - IT
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Therapy of the Young Adult Acute Lymphoblastic Leukemia (ALL): treatment intensification of the pediatric protocol
- NOT YET IDENTIFIED - IT
- More details
-
- ITALY
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia
- NOT YET IDENTIFIED - IT
- More details
-
- Phase II Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Revised Protocol 02 incorporating Protocol Amendment 01
- IRCCS Ospedale Pediatrico Bambino Gesù
- U.O. di Ematologia
- More details
-
- Pilot Phase II Trial on Safety and Activity of Secondary Prophylaxis With Romiplostim in Patients With Non-Hodgkin Lymphoma and Chemotherapy-induced Thrombocytopenia
- IRCCS Ospedale San Raffaele
- Dipartimento di Oncologia
- More details
-
- A phase 1/2 study of SKI-606 in Philadelphia chromosome positive leukemias - IT
- Azienda Ospedaliera San Gerardo
- Unità di Ricerca Clinica
- More details
-
- NETHERLANDS
- Gelderland
- NIJMEGEN
- Gem-CHOP versus CHOP: a randomized study of gemcitabine combined with CHOP in untreated aggressive Non-Hodgkin's lymphoma
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- More details
-
- NETHERLANDS
- Gelderland
- NIJMEGEN
- A phase I/II study of BBR 2778 in combination with Cyclophosphamide, Vincristine and Prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- More details
-
- NETHERLANDS
- Gelderland
- NIJMEGEN
- Immunization of patients with precursor-B-acute lymphoblastic leukemia using in vitro cultured dendritic cells pulsed with synthetic HB-1 peptides and KLH protein
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- More details
-
- NETHERLANDS
- Gelderland
- NIJMEGEN
- A randomized phase III trial comparing dexamethasone with prednisone in induction treatment and bone marrow transplantation with intensive maintenance treatment in adolescent and adult acute lymphoblastic leukemia.
- UMC St Radboud - Universitair Medisch Centrum St Radboud
- Afdeling Hematologie
- More details
-
- NETHERLANDS
- Groningen
- GRONINGEN
- A Randomised Phase III Study On The Effect Of The Chimeric Anti-CD20 Monoclonal Antibody (Mabthera) During Sequential Chemotherapy Followed By Autologous Stem Cell Transplantation In Patients With Relapse B-Cell Non-Hodgkin Lymphoma
- UMCG - Universitair Medisch Centrum Groningen
- Afdeling Hematologie
- More details
-
- NETHERLANDS
- Noord-Holland
- AMSTERDAM
- Low dose radiotherapy (2x 2 Gy)in low grade Non-Hodgkin lymphomas
- Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
- Groep Tumorbiologie
- More details
-
- NETHERLANDS
- Zuid-Holland
- ROTTERDAM
- Efficacy and Safety of Recombinant Asparaginase in Infants (<1 Year) With Previously Untreated Acute Lymphoblastic Leukaemia - Phase II Clinical Trial
- Erasmus MC - Erasmus Medisch Centrum
- Afdeling Kinderoncologie en -hematologie
- More details
-
- NETHERLANDS
- Zuid-Holland
- ROTTERDAM
- Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
- Erasmus MC - Erasmus Medisch Centrum
- Kankercentrum Daniel den Hoed
- More details
-
- NORWAY
- Trøndelag
- TRONDHEIM
- ALL2008 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion (Phase III) - NO -
- Trondheim University Hospital
- More details
-
- NORWAY
- Trøndelag
- TRONDHEIM
- Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol - NO -
- Trondheim University Hospital
- More details
-
- Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia - PL
- Uniwersytet Medyczny im. Karola Marcinkowskiego - University of Medical Sciences
- Department of Paediatric Oncology, Hematology and Hematopoietic Stem Cell Transplantation
- More details
-
- Phase II study of cisplatin with gemcitabine in fixed dose rate infusion and dexamethasone in second-line in patients with aggressive non-Hodgkin's lymphoma (terminated)
- Hospital Universitario Virgen de la Victoria
- Servicio de Oncología (HUVV)
- More details
-
- SPAIN
- Castilla - León
- SALAMANCA
- A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (completed)
- Complejo Asistencial Universitario de Salamanca
- Servicio de Hematología
- More details
-
- SPAIN
- Castilla - León
- SALAMANCA
- LAL-BR/2001: Study Treatment to Low Risk ALL (Phase IV)
- Complejo Asistencial Universitario de Salamanca
- Servicio de Hematología
- More details
-
- PROCEDYTE: An Open, Prospective, Multicentre Clinical Trial With Historic Control to Determine Efficacy and Safety of Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration of Patients Between 16 and 30 Years Old With Standard Risk Acute Lymphoblastic Leukemia (ALL) (Phase III)
- ICO Badalona
- More details
-
- Treatment of High Risk Adult Acute Lymphoblatic Leukemia (Phase IV)
- ICO Badalona
- More details
-
- Burkimab: Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old) (Phase II)
- ICO Badalona
- More details
-
- LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia (Phase IV)
- ICO Badalona
- More details
-
- LAL-BR/2001: Study Treatment to Low Risk ALL (Phase IV)
- ICO Badalona
- More details
-
- Multicenter, Prospective, Open Label Trial, Uncontrolled to Determine the Efficacy and Safety of Depocyt ® for the Treatment of CNS Relapse in Adult Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma (Phase II) (completed)
- ICO Badalona
- More details
-
- LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive (Phase IV) (terminated)
- ICO Badalona
- More details
-
- Positive Ph Acute Lymphoblastic Leucemia With Intensive Induction Chemotherapy and Glivec, Before and After the Hematopoetic Progenitor Transplant (Phase II) (terminated)
- ICO Badalona
- More details
-
- BLAST - A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Phase II) - ES
- ICO Badalona
- More details
-
- PETHEMA LAL-07FRAIL: Treatment Protocol For Acute Lymphoblastic Leukemia Fragile Patients Ph' Negative Over 55 Years
- ICO Badalona
- More details
-
- Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
- ICO Badalona
- More details
-
- Protocol Treatment for Acute Lymphoblastic Leukemia Ph '(Bcr / Abl) Positive Patients Aged> 55 Years Old
- ICO Badalona
- More details
-
- Treatment of Acute Lymphoblastic Leukemia High Risk BCR / ABL Negative in Adults (Phase IV)
- ICO Badalona
- More details
-
- A phase Ia/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with imatinib-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ALL, and other hematologic malignancies - ES
- Hospital Clínic de Barcelona
- Servicio de Hematología
- More details
-
- A Phase II Multicenter, Open-Label, Clinical And Pharmacokinetic Study of Aplidin® As A 1-Hour Weekly IV Infusion, in Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (completed)
- Hospital Clínic de Barcelona
- Servicio de Hematología
- More details
-
- LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia (Phase IV)
- Hospital Universitari Vall d'Hebron. Area Materno Infantil
- Servicio de Hematología y Oncología Pediátrica
- More details
-
- LAL-BR/2001: Study Treatment to Low Risk ALL (Phase IV)
- Hospital Universitari Vall d'Hebron. Area Materno Infantil
- Servicio de Hematología y Oncología Pediátrica
- More details
-
- A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES
- Hospital de la Santa Creu i Sant Pau
- Servicio de Hematología Clínica
- More details
-
- SPAIN
- Cataluña
- ESPLUGUES DE LLOBREGAT
- A Phase II CT to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia
- Hospital Universitari Sant Joan de Déu
- Servicio de hematología clínica pediátrica (HSJDBCN)
- More details
-
- SPAIN
- Comunidad Valenciana
- VALENCIA
- A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES
- Hospital Clínico Universitario de Valencia
- Servicio de Hematología y Oncología Médica
- More details
-
- SPAIN
- Comunidad Valenciana
- VALENCIA
- Treatment of High Risk Adult Acute Lymphoblatic Leukemia (Phase IV)
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- More details
-
- SPAIN
- Comunidad Valenciana
- VALENCIA
- Burkimab: Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old) (Phase II)
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- More details
-
- SPAIN
- Comunidad Valenciana
- VALENCIA
- A Multi-Center, Multi-National, Historical Cohort Controlled Study to Evaluate Efficacy and Safety of Transplantation of StemEx®, Umbilical Cord Blood Stem and Progenitor Cells Expanded Ex Vivo, in Subjects With Hematologic Malignancies Following Myeloablative Therapy (Phase II/III) - ES
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- More details
-
- SPAIN
- Comunidad Valenciana
- VALENCIA
- DASA-TRAS: Multicenter, Non-randomized Phase II Pilot Study to Assess the Efficacy and Safety of Dasatinib After Allogeneic Stem Cell Transplantation in Patients With de Novo Philadelphia Positive (Bcr-abl +) Acute Lymphoblastic Leukemia
- Hospital Universitario y Politécnico La Fe
- Servicio de Hematología y Hemoterapia
- More details
-
- LAL-BR/2001: Study Treatment to Low Risk ALL (Phase IV)
- Hospital Clínico San Carlos
- Servicio de Hematología y Hemoterapia (H.C. San Carlos)
- More details
-
- Burkimab: Study Multicenter of Optimization of the Treatment of LLA-B and the Burkitt's Lymphoma in Adult Patients (From 15 Years Old) (Phase II)
- Hospital Universitario 12 de Octubre
- Servicio de Hematología (H.U. 12 de Octubre)
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Multicentre, Single Arm, Observational Phase IV Study to Assess the Safety and Efficacy of Nelarabine in Children and Young Adults (up to 21 Years of Age) With Relapsed or Refractory T-lineage Acute Lymphoblastic Leukaemia or Lymphoblastic Lymphoma
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- PREDICT: Plerixafor and G-CSF for the Mobilisation of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM). Safety Study in a General Autologous Transplant Population (Phase III) (completed)
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A phase 1/2 study of SKI-606 in Philadelphia chromosome positive leukemias - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- An Open-label, Dose-escalating Study to Investigate the Safety and Tolerability of R7159 Monotherapy in Patients With CD20+ Malignant Disease (Phase II) - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis (Phase II)
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- PACE : A pivotal phase 2 trial of ponatinib (AP24534) in patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia - ES
- Not yet identified - ES
- More details
-
- SPAIN
- Madrid
- NOT YET IDENTIFIED - ES
- An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) - ES
- Not yet identified - ES
- More details
-
- TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia - ES
- Hospital de Navarra
- Servicio de Hematología y Hemoterapia (H. Navarra)
- More details
-
- SWEDEN
- Stockholms läns landsting
- STOCKHOLM
- ALL2008 NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion (Phase III) - SE -
- Karolinska University Hospital - Solna
- Childhood cancer research unit
- More details
-
- UNITED KINGDOM
- Cambridgeshire
- CAMBRIDGE
- AmBiGuard: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia
- Gilead Sciences International Limited
- More details
-
- UNITED KINGDOM
- Devon
- PLYMOUTH
- A Phase II study to evaluate the safety and efficacy of Marqibo® in relapsed acute lymphoblastic leukaemia
- Derriford Hospital
- Clinical Haematology
- More details
-
- UNITED KINGDOM
- Greater London
- LONDON
- UKALL 14: A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia (Phase III)
- Cancer Institute
- UCL Cancer Institute
- More details
-
- UNITED KINGDOM
- Greater London
- LONDON
- An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor (Phase II/III)
- Faculty of Medicine - Imperial College of London
- Centre for Haematology
- More details
-
- UNITED KINGDOM
- Greater London
- LONDON
- International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia (Phase III)
- Great Ormond Street Hospital NHS Foundation Trust
- Haematology Outpatient's Department
- More details
-
- UNITED KINGDOM
- Greater London
- LONDON
- LK 2006 10 (Interfant 06): International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia (Phase III)
- Great Ormond Street Hospital NHS Foundation Trust
- Department of Haematology/Oncology
- More details
-
- UNITED KINGDOM
- Greater London
- LONDON
- CD19TPALL: Immunotherapy With CD19zeta Gene-modified EBV-specific CTLs After Stem Cell Transplant in Children With High-risk Acute Lymphoblastic Leukaemia (Phase I/II)
- Great Ormond Street Hospital NHS Foundation Trust
- Great Ormond Street Hospital for Children NHS Trust (GOSH)
- More details
-
- UNITED KINGDOM
- Greater London
- LONDON
- MARALL: Phase I/II Study Combining Humanised Anti-CD20 (Veltuzumab), Anti-CD22 (Epratuzumab) and Both Monoclonal Antibodies With Intensive Chemotherapy in Adults With Recurrent B-precursor Acute Lymphoblastic Leukaemia
- St Bartholomew's Hospital, Barts and The London NHS Trust
- Department of Medical Oncology
- More details
-
- UNITED KINGDOM
- Greater Manchester
- MANCHESTER
- APL-A-005-02: Phase I - II clinical and pharmacokinetic study of Aplidin (APL) as a 3-hour intravenous infusion every 2 weeks, in children with refractory or relapsed malignant tumours and leukaemia
- Royal Manchester Children's Hospital
- Department of Paediatric Oncology
- More details
-
- UNITED KINGDOM
- Greater Manchester
- MANCHESTER
- ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (Phase III)
- The Christie NHS Foundation Trust
- Paediatric & Adolescent Oncology Unit
- More details
-
- UNITED KINGDOM
- Greater Manchester
- MANCHESTER
- An Open-label, Randomized Phase II/III Study to Compare the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)
- The Christie NHS Foundation Trust
- Paediatric & Adolescent Oncology Unit
- More details
-
- UNITED KINGDOM
- Greater Manchester
- MANCHESTER
- EsPhALL: European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib (phase II)
- The Christie NHS Foundation Trust
- Paedriatic & Adolescent Oncology Unit
- More details
-
- UNITED KINGDOM
- Greater Manchester
- NOT YET IDENTIFIED - UK
- PACE : A pivotal phase 2 trial of ponatinib (AP24534) in patients with refractory chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia
- NOT YET IDENTIFIED - UK
- More details
-
- UNITED KINGDOM
- Greater Manchester
- NOT YET IDENTIFIED - UK
- Phase II pharmacokinetic study to assess the age-dependency in the clearance of Doxorubicin in paediatric patients with Solid Tumours and Leukaemia
- NOT YET IDENTIFIED - UK
- More details
-
- UNITED KINGDOM
- Merseyside
- LIVERPOOL
- A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL and other hematological malignancies - UK
- Royal Liverpool University Hospital
- Department of Haematology
- More details
-
- UNITED KINGDOM
- South Yorkshire
- SHEFFIELD
- MRC UKALL 2003: Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial UKALL 2003 (Phase III)
- The Sheffield Children's Hospital
- Roald Dahl Paediatric Haematology Centre
- More details
-
- UNITED KINGDOM
- South Yorkshire
- SHEFFIELD
- LK 1999 05: International Collaborative Treatment Protocol for Infants under one year with Acute Lymphoblastic Leukaemia (Phase III)
- The Sheffield Children's Hospital
- Roald Dahl Paediatric Haematology Centre
- More details
-
- UNITED STATES
- New York
- NEW YORK
- Phase III Randomised Study on Liposomal Cytarabine (DepoCyte®) vs. Intrathecal Triple for CNS-Treatment During Maintenance Therapy in High-Risk Acute Lymphoblastic Leukemia Patients in NOPHO ALL 2008 Treatment Protocol - SE -
- Schneider Children's Hospital
- Department of Pediatrics
- More details
